NorwayNorway

Pronova opens up Japanese market

30.09.2011

Lysaker/Osaka - Pronova Biopharma SA is set on entering the Japanese market with its TAK-085 (omega-3-acid ethyl esters 90) for the treatment of hyperlipidemia. Pronova's partner Takeda Pharmaceutical Company Limited submitted a New Drug Application (NDA) to the Ministry of Health, Labour and Welfare. Their application is the fruit of a long-standing relationship. In 2005, Takeda and Pronova entered into a License and Supply Agreement in which Takeda was granted the exclusive development and marketing rights to this product in Japan. TAK-085, discovered by Pronova, is the omega 3-derived prescription drug containing highly concentrated and purified EPA-E (eicosapentaenoic acid ethyl ester) and DHA-E (docosahexaenoic acid). The submission is based on the results of the phase 3 clinical trial to evaluate the efficacy and safety of TAK-085 in comparison with an active comparator EPA product already marketed in Japan. The trial demonstrated that 4g per day of TAK-085 was statistically superior to 1.8g per day of the EPA. The drug is already on the market in 56 countries including the U.S. and most European countries.

NorwayNorway

19.03.2008

Oslo – Photocure ASA, one of the Norwegian biotech companies established around the Radium Hospital in Oslo and listed on the Oslo Stock Exchange since 2000, has proposed a demerger of its cancer-focused drug delivery subsidary...

Norway, BioFundingNorway

19.02.2008

Tromsø/Oslo – Two Norwegian companies have raised fresh money to further develop their therapeutic programmes. Tromsø-based Lytix Biopharma AS recently completed a private placement of EUR6.2m (NOK 50m). The money will be used to...

Norway, BioFundingNorway

19.02.2008

Oslo – Norwegian company Aqua Bio Technology ASA kicked off the new year with an initial public offering on the new Oslo Axess Exchange. The first day of public trading was January 10. Compared to a listing on the Oslo Børs,...

Norway, BeNeLuxNorway

22.11.2007

Brussels/Oslo – Belgian antibody fragment specialist Ablynx has raised a75 million in its IPO through the sale of 10.7 million shares at a7 on the Brussels Euronext stock market Eurolist. The company received a total valuation...

NorwayNorway

21.11.2007

Lysaker – Norwegian company Pronova BioPharma ASA, specialists in omega-3-derived products, has raised EUR73.7 million (NOK575 million) through the sale of 25 million shares at EUR2.9 (NOK23) per share in an IPO on the Oslo Stock...

NorwayNorway

24.09.2007

Oslo – The Research Council, in cooperation with Innovation Norway and the Industrial Development Corporation of Norway (SIVA), has appointed an international group of experts to map out the potential of the bioprospecting field...

NorwayNorway

11.07.2007

Oslo – The Norwegian biobank project HUNT, which is attached to the Norwegian University of Science and Technology and based in the region of Nord-Trondelag has established a commercial company to facilitate relationships with...

NorwayNorway

11.07.2007

Oslo – Norwegian antibody therapeutics company Affitech AS has signed a research and licensing agreement with Swiss pharma company Roche to produce human monoclonal antibodies against an unspecified oncology target. Affitech will...

NorwayNorway

18.05.2007

Oslo – The Norwegian government has announced funding for functional genomics research of around €113 million (NOK 420million) over the coming five years. The money is being granted for the continuation of the funding...

NorwayNorway

16.05.2007

Oslo – Algeta ASA, a Norwegian cancer therapeutics company, has completed its listing on the Oslo Stock Exchange. The shares began trading on 27 March. The initial public offering raised gross proceeds of approximately NOK 250...

Displaying results 41 to 50 out of 92

< Previous 41-50 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-norway/browse/4/article/pronova-opens-up-japanese-market.html

Events

All Events

Stock list

All quotes

TOP

  • WILEX2.48 EUR3.77%
  • 4SC1.12 EUR2.75%
  • VITA 344.00 EUR2.04%

FLOP

  • ADDEX2.99 CHF-7.14%
  • BIOFRONTERA2.18 EUR-5.22%
  • SARTORIUS94.26 EUR-3.32%

TOP

  • SANTHERA92.00 CHF35.4%
  • PAION2.98 EUR23.1%
  • CO.DON3.02 EUR20.8%

FLOP

  • ADDEX2.99 CHF-25.8%
  • EVOTEC3.00 EUR-19.4%
  • MEDIGENE4.03 EUR-13.3%

TOP

  • SANTHERA92.00 CHF2188.6%
  • CO.DON3.02 EUR235.6%
  • PAION2.98 EUR186.5%

FLOP

  • CYTOS0.24 CHF-94.0%
  • MERCK KGAA67.23 EUR-41.0%
  • THERAMETRICS0.09 CHF-40.0%

No liability assumed, Date: 17.09.2014


Current issue

All issues

Product of the week

Products